Structure Therapeutics CTO reports tax share withholding

Structure Therapeutics Inc. Chief Technology Officer Ma Yingli reported a tax-related share disposition tied to vesting of a restricted share unit award.

Accepted by SEC EDGAR 03/05/2026 - 06:20 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Structure Therapeutics Inc. Chief Technology Officer Ma Yingli reported a tax-related share disposition tied to vesting of a restricted share unit award. On this transaction date, 11,313 Ordinary Shares were withheld by the company at a price of $20.99 per share to cover income tax obligations. After this tax-withholding disposition, Ma Yingli directly owned 107,391 Ordinary Shares. The company notes that each American Depositary Share represents three Ordinary Shares.

Insider Trade Summary

Exercise Price or Tax Liability: 11,313 shares

Exercise Price or Tax Liability 1 txn

Insider Ma Yingli

Role CHIEF TECHNOLOGY OFFICER

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	11,313	$20.99	$237K

Holdings After Transaction: Ordinary Shares — 107,391 shares (Direct)

Holdings Before and After: Ordinary Shares, 118,704 to 107,391 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.
2. F2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Structure Therapeutics (GPCR) report for Ma Yingli?

Structure Therapeutics reported a tax-withholding disposition for Chief Technology Officer Ma Yingli. The company withheld 11,313 Ordinary Shares to satisfy income tax obligations arising from the vesting of a restricted share unit award, rather than an open market sale of shares.

How many Structure Therapeutics (GPCR) shares were withheld for taxes in this Form 4?

The Form 4 shows 11,313 Ordinary Shares withheld by Structure Therapeutics. These shares were used to cover income tax obligations connected to the vesting of a restricted share unit award, reflecting a non-market, tax-related transaction instead of a discretionary sale.

What is Ma Yingli’s share ownership in Structure Therapeutics (GPCR) after the transaction?

Following the tax-withholding disposition, Chief Technology Officer Ma Yingli directly owned 107,391 Ordinary Shares of Structure Therapeutics. This figure reflects her holdings after the company withheld shares to satisfy income tax obligations tied to a restricted share unit vesting event.

Was the Structure Therapeutics (GPCR) Form 4 transaction an open market sale?

The Form 4 describes a tax-withholding disposition, not an open market sale. Shares were withheld by Structure Therapeutics to satisfy income tax obligations from the vesting of a restricted share unit award, using transaction code F for payment of tax liability with securities.

How are Structure Therapeutics (GPCR) Ordinary Shares related to its ADSs?

According to the filing, each American Depositary Share of Structure Therapeutics represents three Ordinary Shares. This ratio links the company’s Ordinary Shares, as reported in the Form 4, to the ADSs that may trade in public markets for investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ma Yingli

(Last) (First) (Middle)

C/O STRUCTURE THERAPEUTICS INC.

601 GATEWAY BLVD., SUITE 900

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Structure Therapeutics Inc. [ GPCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF TECHNOLOGY OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	03/03/2026		F		11,313(2)	D	$20.99	107,391	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents three Ordinary Shares of the Issuer.

2. Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a restricted share unit award.

	/s/ Jun Yoon, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.